Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era

American Journal of Transplantation

Volumn 13, Issue 6, 2013, Pages 1512-1522

  Evens, A M ^a   Choquet, S ^b   Kroll Desrosiers, A R ^c   Jagadeesh, D ^a   Smith, S M ^d   Morschhauser, F ^e   Leblond, V ^b   Roy, R ^f   Barton, B ^c   Gordon, L I ^f   Gandhi, M K ^g   Dierickx, D ^h   Schiff, D ⁱ   Habermann, T M ^j   Trappe, R ^k  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f NORTHWESTERN UNIVERSITY   (United States)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

CNS; lymphoma; prognosis; PTLD; rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROCARBAZINE; RITUXIMAB; STEROID; TACROLIMUS; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN DISEASE; BRAIN RADIATION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROSURGERY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY CENTRAL NERVOUS SYSTEM POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; WORLD HEALTH; YOUNG ADULT;

EID: 84878517158     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12211     Document Type: Article

References (38)

1. Jagadeesh D, Woda BA, Draper J, Evens AM., Post transplant lymphoproliferative disorders: Risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13: 122-136.
2. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046.
3. Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, et al. Post-transplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc 2005; 37: 954-955.
4. Penn I, Porat G., Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240-244.
5. Cavaliere R, Petroni G, Lopes MB, Schiff D., Primary central nervous system post-transplantation lymphoproliferative disorder: An International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116: 863-870.
6. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, et al. Identification of prognostic factors in 61 patients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778.
7. Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25: 4902-4908.
8. Nalesnik MA., Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 9-18.
9. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574-7582.
10. Nabors LB, Palmer CA, Julian BA, Przekwas AM, Kew CE., Isolated central nervous system post-transplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 2009; 9: 1243-1248.
11. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191-196.
12. Mamzer-Bruneel MF, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622-3632.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
14. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
15. Abrey LE, Yahalom J, DeAngelis LM., Treatment for primary CNS lymphoma: The next step. J Clin Oncol 2000; 18: 3144-3150.
16. Knight J, Tsodikov A, Cibrik D, Ross C, Kaminski M, Blayney D., Lymphoma after solid organ transplantation: Risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27: 1-12.
17. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576.
18. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
19. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, Gomez-Codina J, Salar A, Bailen A, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92: 1489-1494.
20. Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 2008; 49: 1738-1744.
21. Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775-780.
22. Dotti G, Fiocchi R, Motta T, Mammana C, Gotti E, Riva S, et al. Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 2002; 74: 1095-1102.
23. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, et al. Post-transplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity ? J Clin Oncol 1998; 16: 2052-2059.
24. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH., Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity ? Am J Surg Pathol 2000; 24: 375-385.
25. Schaffer K, Hassan J, Staines A, Coughlan S, Holder P, Tuite G, et al. Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, post-transplant times, and transplant indications. Liver Transpl 2011; 17: 1420-1426.
26. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of post-transplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165-1171.
27. Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ., Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011; 96: 1002-1007.
28. Choquet S, Mamzer BM, Hermine O, Porcher R, Nguyen QS, Davi F, et al. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 67-80.
29. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, et al. Post-transplant lymphoproliferative disorders: Improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 67-77.
30. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
31. Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, et al. Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder(bigstar). Am J Transplant 2011; 11: 336-347.
32. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for post-transplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
33. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 2009; 374: 1512-1520.
34. Taylor AL, Bowles KM, Callaghan CJ, Wimperis JZ, Grant JW, Marcus RE, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant post-transplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006; 82: 375-381.
35. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S., CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274.
36. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: The memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol 2006; 24: 5711-5715.
37. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272.
38. Peduzzi P, Concato J, Feinstein AR, Holford TR., Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48: 1503-1510.